ArticleJournal of asthma and allergy2024
Main Airborne Pollen Species and Characteristics of Allergic Rhinitis Patients with Pollen-Related Allergies in 13 Northern Chinese Cities.
Article in Journal of asthma and allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Engineering tolerogenic mRNA-LNPs for allergen-specific immune reprogramming in pollen allergy.Materials today. Bio · 2026Article
- Unraveling the increasing burden of allergies: Spatiotemporal dynamics of pollen allergy risk in China.Eco-Environment & Health · 2026Article
- Effect of initiation treatment timing on efficacy ofThe World Allergy Organization journal · 2026Article
- Pollen-induced allergic rhinitis in the central region of Inner Mongolia, China: prevalence, risk factors, and regional characteristics.Frontiers in allergy · 2026Article
- Allergic Sensitization to Common Ragweed and Mugwort Pollen Allergens: A 6-Year Single-Center Retrospective Analysis.Journal of immunology research · 2026Review
- Research on pollen allergy in Fuzhou, China: from the online public concern surveys to pollen monitoring.Frontiers in public health · 2026Article
- Changes of Pollen Allergens in Northern China.International archives of allergy and immunology · 2026Review
- Art an 3 as a candidate recombinant antigen for Artemisia pollen immunotherapy: comparative efficacy and mechanistic insights.Frontiers in medicine · 2026Article
- Evaluating stapokibart in the treatment of seasonal allergic rhinitis.Immunotherapy · 2025Review
- Global Ragweed Allergy: Molecular Allergens and Integrated Control Strategies.Journal of asthma and allergy · 2025Review
- Article
- Characteristics of Pollen Concentration Changes in Xi'an and Their Correlation with Allergy-Related Diseases.Journal of asthma and allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pollen allergies have a high prevalence in northern China, whereas, the types of pollen allergens and population characteristics among different regions remain unclear. Objective: To study the species and temporal distribution of the main allergenic pollen, as well as the characteristics of patients with pollen-related allergic rhinitis (AR) in different cities in northern China. Methods: Pollen data were obtained from pollen-monitoring stations in 13 cities of northern China between 2020 and 2021. Questionnaire surveys and allergen testing were conducted in 494 patients with pollen-related allergies from Beijing in Central, Shenyang in Northeast, and Xi'an in Northwest China. Results: In 13 cities of northern China, the main sources of pollen were cypress, poplar, elm, pine, birch and ash in spring, and mugwort, goosefoot, hop and ragweed in autumn. In Northwest China, the spring and autumn pollen periods started earlier and lasted longer than that in Central and Northeast China, and the pollen counts in autumn in was significantly higher than that in Central and Northeast China. Furthermore, the nasal, ocular and respiratory symptom and quality of life scores of AR patients in Northwest China were significantly higher than that in Central and Northeast China. 69.32-73.28% of patients had annual cost of anti-allergic medication between 500-5000 yuan. However, 40.93-48.86% of patients reported minor control of symptoms. Conclusion: Our results can be used as a basis for developing effective prevention and management measures for patients with pollen-related allergy in these regions, including timely pollen monitoring, patient guidance on protective measures, early intervention, and specific immunotherapy, to improve pollen-related allergy management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.